Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2006

View Archived Issues

Takeda presents highlights of previous nine months

Ferritin synthesis increased by small molecule binding to mRNA

Protection for gentamicin-evoked nephrotoxicity / News in Context

Pivotal phase II/III MS trial of MBP-8298 recommended to continue

Phase I trial investigates APD-668 for type 2 diabetes

ARYx completes Series E financing

Phase I SBIR grant supports preclinical work for ALS-886 for stroke

Oscient acquires expanded rights to ramoplanin

G2 Therapies and Novo Nordisk to collaborate on antiinflammatory therapies

Xyotax receives fast track designation for PS2 women with NSCLC

ReGen Therapeutics to acquire Sciencom

Open-label phase III extension study planned for Alzhemed in North America

FDA approves IND for first phase III bladder cancer trial for Bioniche's MCC

Selective apoptotic agent isolated from an actinomycete

MF-101 studied in phase II trial for treatment of menopausal symptoms

Generic name bremelanotide approved for PT-141

Avrina shows efficacy in eczema

Alvimopan reduces time to recover GI function following bowel resection surgery

NRP-290 bioavailability studied in phase I/II trial

Factor Xa inhibitor shows promise as an antimetastatic agent

COX-2 inhibitors reduce the risk of breast cancer

Recent patents disclose novel antiinfective agents

Novel agents for endocrine-related disorders reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...